Delenex Therapeutics AG

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

The next generation of chimeric antigen receptor T-cell (CAR-T) therapies to be developed, where most companies are at around the same (preclinical) stage, is expected to be aimed at treating solid tu

Start-Up Execs 3-V Biosciences Inc. William McCulloch To: CMO (November) From: CMO, Gloucester Pharmaceuticals Inc. Phone: 650-561-8600 Afferent Pharmaceuticals Inc. Michael M. Kitt, MD Fr

In Vitro Diagnostics 23andMe Inc. J&J's venture arm joins backers in 23andMe's $22.2mm Series C Nov. —New investor Johnson & Johnson Development Corp. has joined current shareholders New Enterprise A